key: cord-0955906-eqvkaz0n
authors: Ackerman, Christina M; Nguyen, Jennifer L; Ambati, Swapna; Reimbaeva, Maya; Emir, Birol; Cabrera, Javier; Benigno, Michael; Malhotra, Deepa; Hammond, Jennifer; Bahtiyar, Mert Ozan
title: Clinical and Pregnancy Outcomes of COVID-19 Among Hospitalized Pregnant Women in the United States
date: 2021-09-03
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab429
sha: 02bdb214d94ad629aecd48ba4d12fe4638720c54
doc_id: 955906
cord_uid: eqvkaz0n

BACKGROUND: Pregnant women with coronavirus disease 19 (COVID-19) may be at greater risk of poor maternal and pregnancy outcomes. This retrospective analysis reports clinical and pregnancy outcomes among hospitalized pregnant women with COVID-19 in the United States. METHODS: The Premier Healthcare Database – Special Release was used to examine the impact of COVID-19 among pregnant women aged 15–44 years who were hospitalized and who delivered compared with pregnant women without COVID-19. Outcomes evaluated were COVID-19 clinical progression, including the use of supplemental oxygen therapy, intensive care unit admission, critical illness, receipt of invasive mechanical ventilation/extracorporeal membrane oxygenation, and maternal death, and pregnancy outcomes, including preterm delivery and stillbirth. RESULTS: Overall, 473,902 hospitalized pregnant women were included, of whom 8584 (1.8%) had a COVID-19 diagnosis (mean [SD] age 28.4 [6.1] years; 40% Hispanic). The risk of poor clinical and pregnancy outcomes was greater among pregnant women with COVID-19 compared with pregnant women without a COVID-19 diagnosis in 2020; the risk of poor clinical and pregnancy outcomes increased with increasing age. Hispanic and Black non-Hispanic women were consistently observed to have the highest relative risk of experiencing poor clinical or pregnancy outcomes across all age groups. CONCLUSIONS: Overall, COVID-19 had a significant negative impact on maternal health and pregnancy outcomes. These data help inform clinical practice and counselling to pregnant women regarding the risks of COVID-19. Clinical studies evaluating the safety and efficacy of vaccines against severe acute respiratory syndrome coronavirus 2 in pregnant women are urgently needed.

As of July 15, 2021, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused >188 million confirmed cases of coronavirus disease 2019 (COVID-19) and >4 million COVID-19attributed deaths worldwide [1] . The burden of COVID-19 has been particularly high in the United States; as of July 15, 2021, there have been >33 million COVID-19 cases resulting in >600,000 COVID-19attributed deaths [1] .

Pregnant women with COVID-19 may be at greater risk of pregnancy and maternal complications [2] [3] [4] . Physiologic changes to the immune and respiratory systems during pregnancy significantly increase the risk of more severe illness from respiratory infections [5] [6] [7] . Furthermore, increased oxygen consumption and edema of the respiratory mucosa during pregnancy [8] heighten susceptibility to severe respiratory pathogens. During the 2009 H1N1 influenza A virus pandemic, pregnancy increased the risk of admission for H1N1 influenza A almost 4-fold [9] . During the SARS-CoV and Middle Eastern Respiratory Syndrome (MERS) outbreaks in 2003 and 2012, respectively, reports indicated that pregnant women with these coronavirus infections experienced poor maternal and fetal outcomes [10, 11] . Data concerning pregnancy outcomes and the ongoing COVID-19 pandemic are limited [12] ; reviews are often based on case series and case studies, which may be inherently biased [13] .

The objective of this retrospective database analysis was 2-fold: to examine the impact of COVID-19 on 1) worsening COVID-19 clinical progression and 2) inpatient pregnancy outcomes, specifically preterm delivery and stillbirth, among pregnant women and women who delivered in the United States by age and race/ethnic categories.

A c c e p t e d M a n u s c r i p t 6 

This retrospective study used the Premier Healthcare Database (PHD; Charlotte, NC, USA) and PHD Special Release (PHD-SR) specially designed for COVID-19 research [14, 15] . The PHD is a US hospital-based, service-level, all-payer database containing administrative data on healthcare encounters at nonprofit, nongovernmental community and teaching hospitals, and health systems from rural and urban areas in all 9 US Census divisions; the data lag between discharge and inclusion in PHD is approximately 6 months.

The PHD-SR contains data from a subset of the facilities included in the PHD that submit data on a monthly or more frequent basis with an approximate data lag time of 1 to 3 weeks from date of discharge. Data were extracted from the PHD for 2019 and PHD-SR for 2020.

Institutional review board approval was not required for this study since the PHD is deidentified and Health Insurance Portability and Accountability Act compliant.

The study included pregnant women aged 15-44 years who were hospitalized and who delivered between April and November 2019 and 2020. Hospitalizations involving pregnancy in the previous year (ie, April to November 2019) were included to allow comparison of pregnant women without COVID-19 in 2020 versus 2019. Pregnancy status was ascertained using diagnosis and procedure codes from MacDonald et al. (2018) [16] ;

International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes were converted to the Tenth Revision (ICD-10-CM) by a professional medical coder.

COVID-19 infection was ascertained using ICD-10-CM diagnosis code U07.1, which became effective on April 1, 2020, and indicates laboratory-confirmed infection with SARS-CoV-2 [17, 18] . For patients with COVID-19, the first hospitalization with evidence of both pregnancy and COVID-19 was retained for analysis. For patients without COVID-19, the A c c e p t e d M a n u s c r i p t 7 first hospitalization involving pregnancy was retained for analysis. For evaluation of pregnancy outcomes (ie, preterm delivery and stillbirth), a subcohort was created limited to women with evidence of livebirth or stillbirth during hospitalization. [16] , including ICD-9-CM codes converted to ICD-10-CM.

P values were calculated for categorical variables using χ 2 tests and for continuous variables using 2-sample t tests (Welch-Satterthwaite for unequal variances, pooled t test for equal variances). Risk ratios (RRs) and 95% confidence intervals (CI) using log-normal distribution were calculated using the PROC FREQ procedure in SAS (v9.4, Cary, North Carolina) to evaluate the impact of COVID-19 on clinical disease progression and pregnancy outcomes among hospitalized pregnant women overall, by age group (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) , and 35-44 years), and by race (Asian, Black, White) and ethnicity (Hispanic and non-Hispanic). Race and ethnicity were collected via self-report, and individuals identifying as >1 race/ethnicity A c c e p t e d M a n u s c r i p t 8 were counted as "Other." Due to the large sample sizes, statistical significance observed between values with similar magnitude may have limited practical significance.

Among 473,902 pregnant women who were hospitalized between April and November 2020 in 720 hospitals, 8584 (1.8%) had a COVID-19 diagnosis (Figure 1) . Mean age was similar between patients with and without COVID-19 (28.4 vs 29.1 y, respectively) and patients with COVID-19 were more likely to be Hispanic (Table 1) . Overall, 445,313 pregnant women were included in the 2020 pregnancy outcomes analysis. The most common primary diagnoses among pregnant women who were hospitalized in 2020 but did not have evidence of a livebirth or stillbirth during the hospitalization (n=28,362) were third trimester preterm labor without delivery (8.8%; ICD10 O60.03); hyperemesis gravidarum with metabolic disturbance (3.3%; ICD10 O21.1); and missed abortion (3.1%; ICD10 O02.1). The distribution of age, race and ethnicity ( Table 1) , and clinical and pregnancy outcomes ( Figure 1 ) was similar between patients without COVID-19 in 2020 compared with the historical control group comprised of pregnant women without COVID-19 from 2019.

Among pregnant women and women who delivered, a higher percentage of women with COVID-19 diagnoses had poor clinical (0.1%-12.9%) and pregnancy outcomes (1.1%-4.9%) compared with pregnant women without a COVID-19 diagnosis (clinical outcomes: 0%-3.0%; pregnancy outcomes: 0.8%-3.7%) in 2020 (Figure 1 ).

Pregnant women with COVID-19 and those who delivered were substantially more likely to need supplemental oxygen (pregnant: RR (Figure 2) . The risk of needing supplemental oxygen, critical illness, and ICU admission was greater among all pregnant women with COVID-19 versus when limited to women who delivered, while risk of maternal death was higher among women who delivered (Figure 2) . The risk ratios for poor clinical outcomes increased with increasing age; similar trends with respect to poor clinical and maternal outcomes among pregnant women versus those who delivered were generally observed across age groups ( Figure 2 ).

An analysis of maternal outcomes by race and ethnicity revealed that the relative risk Within individual race and ethnicity groups, the overall risk of needing supplemental oxygen and being critically ill was generally higher among all pregnant women versus when limited to women who delivered for all race and ethnicity groups (Figure 3) . Notably Asian non-Hispanic and Black non-Hispanic women who delivered had higher risk of needing mechanical ventilation/ECMO versus all pregnant women. Furthermore, pregnant Hispanic women with COVID-19 and Black non-Hispanic women with COVID-19 who delivered were among those at greatest risk of maternal death (Figure 3) . Overall, for all race and ethnicity groups, the risk ratios for poor clinical outcomes increased with age ( Supplementary Figures 1-3) .

Pregnant women with COVID-19 had a higher relative risk of preterm birth (RR 1. Figures 1-3) . Notably, consistent increases for the risk of preterm birth with increasing age were observed for Hispanic and Black non-Hispanic women with COVID-19 (Supplementary Figures 1-3 ).

To our knowledge, this is the largest study to date that investigates the impact of COVID-19 on pregnancy and maternal health in the United States. In this study, higher proportions of pregnant women with COVID-19 experienced poor clinical and pregnancy outcomes compared with pregnant women without COVID-19. The relative risk of poor clinical outcomes among pregnant women with COVID-19 largely depended on age; no uniform trends were observed with respect to poor clinical outcomes and race/ethnicity.

Covid-19 infection was also associated with poor pregnancy outcomes (preterm birth and stillbirth); notably, Hispanic and Black non-Hispanic women experienced consistent increases in the risk of poor pregnancy outcomes with increasing age.

COVID-19 was associated with an overall ≥2-fold increased risk of needing supplemental oxygen, critical illness, ICU admission, receipt of invasive mechanical ventilation/ECMO, and death among pregnant women. Additionally, older pregnant women had a higher risk of worse clinical outcomes. The findings of this study are consistent with a large nationwide survey (N=406,446) that reported that pregnant women with COVID-19 were more likely to be admitted to the ICU, need mechanical ventilation/ECMO, and die compared with pregnant women without COVID-19 [22] . Another nationwide study (N=461,825) reported that pregnant women with COVID-19 had up to 70% increased risk for death compared with nonpregnant women with COVID-19 [23] . The study also reported that pregnant women with COVID-19 aged 25-34 and 35-44 years were more frequently admitted to the ICU, required mechanical ventilation, and died, compared with nonpregnant A c c e p t e d M a n u s c r i p t 12 women with COVID-19 aged 15-24 years [23] . Furthermore, pregnant women aged 35-44 years with COVID-19 had an approximate 4-and 2-fold greater likelihood to require mechanical ventilation and die, respectively, compared with nonpregnant women with COVID-19 [23] . These reports, combined with the data observed in this study, show that pregnant women with COVID-19 may be at greater risk of poor pregnancy and maternal outcomes, especially with increasing age.

During the early stages of the pandemic (March-May, 2020), a study of 105 hospitalized pregnant women reported that the prevalence of stillbirths was 4-fold higher among women with SARS-CoV-2 infection compared with the baseline rate during the analysis period [24] . Likewise, the risk of adverse birth outcomes in pregnant women with COVID-19 in this study was found to be significantly higher compared with COVID-19 negative controls, with a 30% increased risk for preterm delivery and a 40% increased risk of stillbirth. Furthermore, while the risk of adverse birth events increased with increasing age, Similarly, a nationwide study conducted in pregnant women (N=406,446) between April and November 2020 reported that COVID-19 only marginally increased the risk of preterm birth and stillbirth [22] . The low overall prevalence and risk of preterm birth and stillbirths among pregnant women with COVID-19 reported in this study may be a factor of the large and therefore more representative sample size and improved clinical management of COVID-19 during the latter half of 2020.

A c c e p t e d M a n u s c r i p t 13 In this study, the risk of needing supplemental oxygen, critical illness, and ICU admission was greater among all pregnant women with COVID-19 versus when limited to women who delivered, while risk of maternal death was higher among women who delivered.

Of note, hospitalized pregnant women included in this study likely encompassed all pregnancy trimesters, while those who delivered were presumably in their late second trimester or third trimester; additionally, most hospitalizations (94%) were for delivery. To our knowledge, this study is the first to show differences in clinical outcomes between pregnant women with COVID-19 and those who delivered during their hospitalization. The data from this study indicate that there may be differences in how COVID-19 affects women at different trimesters and that women earlier in their pregnancy may be at greater risk of negative outcomes compared with women whose pregnancies have progressed further. These data could be crucial to inform the ongoing care of pregnant women with COVID-19.

Stark racial disparities were observed in this study for both maternal and pregnancy outcomes. Among pregnant women with COVID-19, only Hispanic and Black non-Hispanic women experienced maternal death, and only Hispanic women had a significant association between COVID-19 and preterm delivery. These observations mirror those reported in other national surveillance studies. Studies have reported that Hispanic and Black non-Hispanic women are not only disproportionately represented among SARS-CoV-2 positive cohorts but also face higher risk and rates of mortality from COVID-19 [23, 25, 26] . To our knowledge, this study is the first to report the risk of poor pregnancy outcomes stratified by age and race/ethnicity. The data show that the risk of preterm birth increases with increasing age among Hispanic and non-Hispanic Black women. A 2015-2017 survey reported racial and ethnic disparities in pregnancy outcomes in the United States with Black women facing twice the stillbirth rate compared with White women [27] . Furthermore, in certain regions of the United States, high stillbirth rates were observed among Hispanic women [27] . Many studies 

All data are fully available without restriction; all relevant data are within the manuscript and its Supporting Information files. M a n u s c r i p t M a n u s c r i p t 

World Health Organization. Coronavirus Disease (COVID-19) Dashboard

Characteristics associated with out-of-hospital cardiac arrests and resuscitations during the novel coronavirus disease

SARS-CoV-2 infection and COVID-19 during pregnancy: a multidisciplinary review

Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in New York City: a prospective cohort study

Pneumonia in pregnancy

Preparing for influenza after 2009 H1N1: special considerations for pregnant women and newborns

H1N1 influenza virus infection results in adverse pregnancy outcomes by disrupting tissue-specific hormonal regulation

Respiratory failure and mechanical ventilation in the pregnant patient

H1N1 2009 influenza virus infection during pregnancy in the USA

Management guidelines for obstetric patients and neonates born to mothers with suspected or probable severe acute respiratory syndrome (SARS)

Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis

Maternal and perinatal outcomes in pregnant women infected by SARS-CoV-2: a meta-analysis

Problems with early systematic reviews: the case of coronavirus disease 2019 (COVID-19) in pregnancy

Premier Healthcare Database (COVID-19): Data That Informs and Performs

Premier Healthcare Database: Data That Informs and Performs

Identifying pregnancies in insurance claims data: methods and application to retinoid teratogenic surveillance

Centers for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients With Confirmed Coronavirus Disease (COVID-19)

Centers for Disease Control and Prevention. International Classification of Diseases, Tenth Revision

Clinical characteristics and outcomes of hospitalized women giving birth with and without COVID-19

Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status -United States

SARS-CoV-2 infection among hospitalized pregnant women: reasons for admission and pregnancy characteristics -eight U.S. health care centers

Birth and infant outcomes following laboratoryconfirmed SARS-CoV-2 infection in pregnancy -SET-NET, 16 jurisdictions

Characteristics and maternal and birth outcomes of hospitalized pregnant women with laboratory-confirmed COVID-19 -COVID-NET

Racial and ethnic disparities in fetal deaths -United States

Coronavirus disease 2019 case surveillance -United States

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the

The impact of ethnicity on clinical outcomes in COVID-19: a systematic review

Hospitalization and mortality among Black patients and White patients with COVID-19

COVID-19=coronavirus disease 2019

a Includes Native Hawaiian and Other Pacific Islander, American Indian and Alaska Native, and Some Other race

Editorial/medical writing support was provided by Sheena Hunt, PhD, and Srividya Ramachandran, PhD, of ICON plc (North Wales, PA, USA), and was funded by Pfizer Inc.

As a retrospective database analysis, this study does not include factors necessitating patient consent.

A c c e p t e d M a n u s c r i p t 17 A c c e p t e d M a n u s c r i p t 22